Impact of Laboratory Characteristics and Staff Training on IAC Nuclear/PET Review Deficiencies in Protocols and Reporting
| Characteristic | Adjusted odds ratio for protocol deficiencies | Adjusted odds ratio for reporting deficiencies |
| Number of sites | 1.06 (0.96–1.19) | 1.08 (1.02–1.13) |
| Annual laboratory volume per 1,000 MPI studies | 0.93 (0.84–1.02) | 0.95 (0.86–1.04) |
| Application cycle (per subsequent cycle) | 1.07 (0.96–1.19) | 1.00 (0.91–1.10) |
| Consultant assistance with application | 0.55 (0.41–0.73) | 0.63 (0.48–0.81) |
| Hospital facility | 1.24 (0.85–1.82) | 0.78 (0.54–1.13) |
| Doing general nuclear medicine or PET oncology/neurology | 1.70 (1.12–2.56) | 0.99 (0.66–1.49) |
| Medical director with CBNC status | 0.88 (0.71–1.09) | 0.78 (0.63–0.95) |
| Cardiovascular pathway of medical director | 0.99 (0.79–1.24) | 0.82 (0.66–1.02) |
| Medical director compliant with CME | 0.55 (0.44–0.69) | 0.64 (0.51–0.80) |
| Volume of studies interpreted by medical director, quartiles | ||
| 0–300 | Referent | Referent |
| 301–500 | 0.87 (0.65–1.16) | 0.91 (0.70–1.20) |
| 501–900 | 0.98 (0.74–1.30) | 0.93 (0.71–1.22) |
| 901+ | 1.51 (1.12–2.03) | 1.09 (0.81–1.45) |
| Number of medical staff | 1.16 (1.08–1.24) | 1.04 (0.97–1.11) |
| At least 50% of medical staff with CBNC | 0.85 (0.68–1.06) | 0.90 (0.73–1.11) |
| Number of medical staff compliant with CME | 0.84 (0.77–0.91) | 0.94 (0.87–1.02) |
| Technical director with NCT or PET vs. CNMT or RT(N) | 0.79 (0.55–1.13) | 0.67 (0.47–0.95) |
| Technical director compliant with CE | 0.56 (0.44–0.72) | 0.53 (0.41–0.67) |
| Number of technical staff | 0.92 (0.81–1.04) | 1.00 (0.90–1.11) |
| Number of technical staff compliant with CE | 1.06 (0.92–1.21) | 0.98 (0.87–1.11) |
95% confidence intervals are in parentheses.